Aadi Bioscience Remains Actively Engaged In A Comprehensive Strategic Review To Maximize Shareholder Value

BenzingaNov 6 21:05

Aadi Bioscience Is Completing Wind-down Of PRECISION1 Trial Of Nab-sirolimus In Patients With Solid Tumors Harboring TSC1 Or TSC2 Inactivating Alterations

BenzingaNov 6 21:04

Aadi Bioscience GAAP EPS of -$0.46 In-line, Revenue of $7.21M Beats by $0.61M

Seeking AlphaNov 6 21:03

Aadi Bioscience 3Q Loss/Shr 46c >AADI

Dow JonesNov 6 21:03

Earnings Flash (AADI) AADI BIOSCIENCE Reports Q3 Revenue $7.2M

MT NewswiresNov 6 21:01

Express News | Aadi Bioscience Q3 Operating Expenses USD 20.625 Million

BreakingsNov 6 21:00